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Abstract
Klebsiella pneumoniae (K. pneumoniae) pose an emerging threat to public health 
sector worldwide. They are one of the potent nosocomial pathogens and cause 
variety of infections including pneumonia, septicaemia, wound infections, urinary 
tract infections and catheter-associated infections. From the last two decades, these 
pathogens are becoming more powerful due to the acquisition of resistomes on 
different types of plasmids and transposons. There are four main mechanisms of 
antibacterial resistance such as efflux pump, target alteration, membrane perme-
ability and notably enzymes hydrolysis. K. pneumoniae produce different types of 
enzymes but most importantly extended spectrum-β-lactamase (ESBL), carbapen-
emase and metallo-β-lactamase (MBL). K. pneumoniae carbapenemases (KPCs) 
and New Delhi metallo-β-lactamase (NDM) producing isolates displayed resistance 
not only against the β-lactam drugs (penicillins, cephalosporins and carbapen-
ems) but also to other classes of antibiotics (aminoglycosides and quinolones). 
Therapeutic options available to treat serious infections caused by these extensively 
drug-resistant pathogens are limited to colistin, tigecycline and fosfomycin. Hence, 
combination therapy has also been recommended to treat such bacteria with clinical 
side effects, therefore, new treatment regime must be required. Moreover, we 
are relying on conventional diagnostic tools, however, novel techniques must be 
required for robust identification of multi-drug-resistant bacteria.
Keywords: Klebsiella pneumoniae, antimicrobial resistant mechanisms,  
mortality and morbidity, economic burden
1. Introduction
Klebsiella pneumoniae is one of the notorious pathogens with increase number of 
severe infections and shortage of effective treatment regimes. They are extremely 
resilient pathogens because their success seems to follow the model of “the best 
defence for a pathogen is a good defence” rather than “the best defence for a patho-
gen is a good offense”. K. pneumoniae is a Gram negative, non-motile, capsulated 
and an imperative member of Enterobacteriaceae family. They were firstly identified 
in late nineteenth century and given the name Friedlander’s bacterium [1]. They 
are hermaphrodite and cause both community acquired infections (soil, surface 
water) and significantly hospital acquire infections (medical devices, catheters). 
Importantly, they can reside on different body mucosal surfaces of oropharynx 
and gastrointestinal tract and cause variety of infections including pneumonia, 
bacteraemia, septicaemia, gastritis, wound infections, urinary tract infections, and 
soft tissue surgical infections [2]. From the last 2 decades, K. pneumoniae strains 
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acquired extra genetic traits and become more virulent and antibiotic resistant [3]. 
They develop resistance against a wide range of antibiotics including carbapenems. 
Therefore, they produce (or synthesise) extended spectrum-β-lactamases (ESBL), 
carbapenemases, metallo-β-lactamases (MBLs), New Delhi metallo-β-lactamases 
(NDM) and have many other resistant mechanisms such as efflux pump and 
membranous target alteration.
2. Antimicrobial resistance
Antimicrobial resistance (AMR) defined when a bacterial strain shows resis-
tance against antibiotics that normally inhibit or stop their growth and allow them 
to withstand against drugs. Last 2 decades, there are various AMR pathogens 
have been emerged around the globe such an ESBL producing pathogens, multi-
drug resistant and extensively drug resistant Mycobacterium tuberculosis (MDR, 
XDR-MTB), MBL producing bacteria, methicillin resistance Staphylococcus aureus 
(MRSA) and the advent of NDM producing bacteria. These isolates are almost 
impossible to treat with the existent treatment regime [4]. AMR emerged even since 
the discovery of first antibiotic “penicillin” in 1940 due the natural process of bacte-
ria. Certainly, the genes that confer resistance upon some strains of bacteria precede 
antibiotics by millions of years [5]. Currently, AMR is becoming a big health issue 
around the world due to the irrational, overused and misuse of antibiotics which 
can lead to extra financial burden, prolong hospital stay and even fatal conse-
quences. Unfortunately, currently we deficiency of the novel effective antimicrobial 
compounds, peptides and pipelines antibiotics to combat with emerging superbugs 
which result us facing growing enemy with largely depleted armoury [6].
3.  Mortality, morbidity and economic burden due to antimicrobial 
resistant bacteria
AMR pathogens are one of the main cause of morbidity and mortality in both 
developed and developing countries. According to a published data, around 
700,000 people die due to infections caused by AMR pathogens every year world-
wide and most of the data is still underreported because of poor reporting and sur-
veillance studies [7]. On the other hand, as per The Centre of Disease and Control 
(CDC), above 2 million people get infected due to AMR bacteria with a mortality 
rate of 23,000 each year [8]. Similarly, an Indian study revealed that around 60,000 
neonates die due to AMR infections per year [9]. Likewise, a study conducted in 
Pakistan in 2009 was also documented that 40% neonates die due to MDR and XDR 
pathogens (Escherichia coli, K. pneumoniae, Enterobacter cloacae) isolated from blood 
samples [10]. Another study from Pakistan testified that 37 out of 78 new-borns 
died due to infections caused by MDR-Acinetobacter spp., [11]. Qamar et al., con-
ducted a study in Islamabad, Pakistan also reported 4/9 children died due to NDM 
positive isolates mainly of E. coli and K. pneumoniae [12]. Recently, Khan et al., 
from Karachi, Pakistan also reported that 22 with <1 month of age and 10 were 
elderly patients died due to bacteraemia and septicaemia which was mainly caused 
by NDM positive K. pneumoniae [13]. Highest mortality rate is mainly reported in 
developing countries as compare to developed countries largely in immunocompro-
mised persons. Major risk factors in public sectors hospitals of developing countries 
are, poor hygienic practices of health care workers, irrational use of antibiotics, 
poor sanitation and hygienic facilities, nosocomial pathogens, hospital and wards 
are overcrowded with patients and attended and lack of health care workers, floors 
3Antimicrobial Resistance
DOI: http://dx.doi.org/10.5772/intechopen.82303
and rooms are spilled with sputum and operation theatres are in deliberated condi-
tion and are poorly equipped, contaminated drinking water, more than one patients 
on single bed, presence of insects and flies and most importantly low health care 
budget by the Government [14].
Every year, millions of dollars are spent to tackle the burden of AMR bacterial 
infections around the globe. European Union invested around €1.5 billion annually 
to tackle the infections caused by AMR pathogens which are responsible for around 
23,000 mortalities only in Europe [15]. However, United States of America also 
expenditures above $20 billion to treat the 20 million patients who get infected with 
AMR infection each year [16].
4. Mechanisms of antimicrobial resistance
Since 1990s, bacteria have been becoming gradually more lethal, due to acquisi-
tion of resistomes and develop resistance to different sets of antibiotics. Now a 
day, many bacterial pathogens notably K. pneumoniae are intrinsically resistant to 
various antibiotics or they acquire or encoded antimicrobial resistant genes mainly 
on plasmids as well on chromosomes [17]. There are different mechanisms such 
as conjugation, transformation and transduction in which susceptible strains can 
acquire resistance genes with transposons that eventually support different resis-
tance genes to incorporate with host chromosome or plasmids. Presently, there are 
four fundamental mechanisms of bacterial drug resistance (1) target alteration  
(2) modification in membrane permeability (3) efflux pump and (4) antibiotic 
degradation by enzymes as shows in Figure 1 [18]. In K. pneumoniae both the efflux 
pump and enzymatic degradation of different antibiotics are more efficient as 
compare to other two mechanisms.
Figure 1. 
Mechanism of antimicrobial resistance.
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4.1 Target alteration of the antibiotics
In general, many antibiotics bind to different bacterial target sites with high 
affinity. So, most of the bacteria including K. pneumoniae alter the target sites 
and structure to block or inhibit the efficient binding sites [19]. In K. pneumoniae, 
antibiotic resistance occurs due to target modification in lipopolysaccharides (LPS), 
which is interceded by the activation of PmrA/PmrB two component regulatory 
system (TCRS). Moreover, another TCRS, PhoP/PhoQ contributes to produce poly-
myxin resistance by indirectly activating the PmrA/PmrB TCRS via PmrD linker 
protein. Similarly, inactivation of the PhoQ/PhoP negative regulator encoded by 
mgrB gene has also been identified to play a prominent role in polymyxin resistance 
in K. pneumoniae [20]. There are various pathogens that cause different infections 
and develop resistance even against single point mutation of resistant genes that 
encode an antibiotic target. These resistant strains then further produce numerous 
copies of bacteria [21].
4.2 Modification in membrane permeability
Outer membrane of the bacteria is first line barrier to protect the microorgan-
isms against unfavourable environment including chemical and biological materi-
als. In comparison, majority of the Gram-negative rods (GNR) are intrinsically less 
permeable to various antibiotics because of outer membrane barrier than Gram 
positive bacteria [22]. In the cell wall of Enterobacteriaceae family including K. 
pneumoniae contains various outer membrane proteins (Omps) such as OmpA, 
OmpF and OmpC and the hydrophilic antibiotics can cross through these Omps 
by diffusion. These proteins are involved in adhesion to other cell surfaces, main-
tenance of cell structure and regulation of transport of bactericidal agents and 
nutrition. OmpF expression is regulated at the posttranscriptional level via the micF 
RNA, and many different environmental stresses impact the OmpC/OmpF ratio via 
changes in micF levels. The expression of micF is increased along with that of OmpF 
at high OmpR-P concentrations. The expression of micF is also induced by toxic 
agents, such as paraquat and weak acids, by the SoxS, MarA, and Rob transcrip-
tion factors, which bind to the same sequence element in the micF promoter and 
they down regulate the synthesis of OmpF at transcriptional level (Figure 2) [23]. 
Therefore, the bacteria showed resistance by limiting the antibiotics entry in to the 
cell by the down regulation or replacement of porins with more selective channels. 
However, recent data showed that the loss of porins expression play a significant 
role to produce resistance to new drugs (cephalosporins and carbapenems), to 
which resistance is manly mediated by the enzyme degradation [24]. OmpA is one 
of the major protein of K. pneumoniae that prevent the activation of airway epithe-
lial and loss of this protein make the bacteria susceptible. There are two important 
Omps in K. pneumoniae; OmpK35 and OmpK36 that allow the hydrophilic mol-
ecules such as nutrients and carbapenems to diffuse into bacteria. Moreover, K. 
pneumoniae also contain two alternative proteins; KpnO and OmpK26. Any muta-
tion in OmpK36, OmpK26 and KpnO leads to increased resistance to cephalosporin 
and carbapenems [25].
4.3 Increased efflux pumps
Efflux pumps are the active transport mechanisms that expel out antibiotics 
from bacterial cell and play a vital role to develop intrinsic resistance against 
broad range of antibiotics in GNR [18]. Currently, there are several MDR 
efflux pumps are present in bacteria including FuaABC in Stenotrophomonas 
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maltophilia, MedeA in Streptococcus mutans and AcrAB, KexD and more recently 
OqxAB efflux pumps in K. pneumoniae [26, 27]. In K. pneumoniae, most efficient 
antimicrobial resistant efflux pump is AcrAB, which is not only expel out the 
β-lactam, quinolones and chloramphenicol but also the host derived antimicro-
bial agents such as human antimicrobial peptides and human bronchoalveolar 
lavage fluid [25]. Recently, newly emerging OqxAB efflux pump has been recog-
nised in different parts of the world that conferring resistance to quinolones and 
chloramphenicol [27].
4.4 Enzymatic hydrolysis of the antibiotics
In K. pneumoniae, the most potent and significant antimicrobial resistant 
mechanism is enzymatic hydrolysis of wide range of antibiotics including β-lactam, 
quinolones, aminoglycosides and macrolides [18]. β-lactamases are the enzymes 
that hydrolyze the effect of β-lactam drugs by attacking on their β-lactam ring. 
Currently, a total of 4037 β-lactam enzymes have been identified and mong these 
1327 are class A, class B (n = 581), class C (n = 1359) and 660 belong to class D [28]. 
K. pneumoniae encode for many β-lactamases such as ESBLs, carbapenemases and 
MBLs. ESBLs and carbapenemases contain important subclasses of β-lactamase 
enzymes such as imipenemase (IMP), Verona integron encoded metallo-β-
lactamase (VIM), K. pneumoniae carbapenemases (KPC), oxacillinase (OXA) and 
recently NDM [29].
4.4.1 Classification of β-lactamases
These enzymes are broadly classified into two main scheme one is Ambler 
Molecular classification scheme which is based on amino acid sequence and is 
widely acceptable and secondly, Bush Jacoby classification scheme which is based 
on biochemical properties [30]. Ambler class is further divided in to four major 
sub-classes A, B, C, and D based on conserved and distinguished amino acid 
Figure 2. 
Down regulation mechanism of outer membrane proteins (OMPs) in gram negative bacteria.
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motifs. Among these, class A, C, and D are the serine carbapenemases that hydro-
lyzed their substrate through active site by forming acyl groups and require serine 
as a cofactor for their activity. However, class B enzymes are the MBLs that utilised 
at least one zinc ion at their active site to hydrolyze the β-lactam antibiotics. MBLs 
are further classified into three super families B1, B2 and B3 [31]. However, Bush-
Jacoby-Medeiros classification scheme is divided into three major groups; class C 
(Group 1 cephalosporinases), class A and D (Group 2 Serine β-lactamases) and 
class B (Group 3 MBLs). These are further divided in to several different subgroups 
as shows in Table 1 [30].
4.4.2 Extended spectrum-β-lactamase producing K. pneumoniae
ESBL are the enzymes that hydrolyze the extended spectrum drugs mainly 
cephalosporins. ESBL producing Enterobacteriaceae mainly the K. pneumoniae 
and E. coli is becoming one of the serious threat to the public health sectors. 
According to World Health Organisation (WHO), around 50% of ESBL produc-
ing K. pneumoniae becomes the endemic in many parts of the world and it causes 
30% resistance rate in the community [32]. In 1965, first β-lactamase enzyme 
Temoneria (TEM-1) and sulphydryl variable (SHV-1) has been identified. In 
1983, first case SHV-2 and TEM-3 has been documented in Germany and France 
respectively. Similarly, in 1989, USA also reported ESBL producing K. pneu-
moniae and E. coli. Since then, incidence of these enzymes markedly sporadic 
from one region to another [33]. ESBL producing K. pneumoniae displayed resis-
tance to clinically effective extended spectrum cephalosporins and monobactam 
and left limited treatment options. Moreover, ESBL producing K. pneumoniae 
has become major ESBL carrying bacteria associated with nosocomial infections 
and outbreak during 1990 to 2000. Later, these pathogens acquired variants 
of ESBL such as CTX-M, TEM and SHV. There are various types of ESBLs have 
been identified throughout the world. Up till now, TEM (n = 227) are the most 
predominant type of ESBLs followed by CTX-M (n = 207), SHV (n = 203), VEB 
(n = 19) and PER (n = 9) [28]. Majority of these ESBLs have been reported in 
Enterobacteriaceae notably K. pneumoniae and E. coli. ESBLs producing K. pneu-
moniae have also become an important hospital acquired pathogen. In China, 
around 50% of the hospital acquired infections are caused by CTX-M-14 and 
CTX-M-15 ESBL producing K. pneumoniae [34]. Recently, these ESBL producing 
K. pneumoniae were also reported from community such as water, soil and veteri-
nary settings [35]. In Asia, SHV is the predominant genotype of ESBL and early 
SHV-5 and SHV-12 enzymes were documented in Korea and Japan. However, in 
Europe and south east Asia (India and Pakistan), CTX-M-2, CTXM-3, CTX-M-
14 and CTX-M-15 producing Enterobacteriaceae at its rise. However, in Japan, 
SHV-12 and CTX-M-3 and CTXM-14 have been predominantly reported in K. 
pneumoniae and E. coli. In Indo-Pakistan region, most of the clinical isolates of K. 
pneumoniae encoded for TEM, CTX-M and SHV. Two highly populated countries 
in the world (China and India) represents the largest reservoir of CTX-M in the 
world [36].
4.4.3 AmpC producing K. pneumoniae
AmpC are the β-lactam enzymes that belong to the ambler class C of 
β-lactam. These enzymes hydrolyze cephalosporins antibiotics and produce 
resistance against penicillin, second and third generation cephalosporins and 
cephamycin. Moreover, these enzymes can also convey resistance to combina-
tion of these antibiotics along with β-lactam inhibitors. The versatility of the  
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K. pneumoniae is to encode various β-lactam resistant genes on their transferable 
plasmids that able them to spread AmpC like resistomes in to other species [30]. 
Plasmid mediated AmpC gene was firstly identify during 1980s in  
Molecular 
class 
(subclass)
Bush 
Jacoby 
groups
Main 
substrate
Defining 
characteristic(s)
Representative Bacteria
A 2a Penicillins Increased 
hydrolysis of 
benzylpenicillin
PC1
A 2b Penicillins 
and early 
Cephalosporins
Hydrolysis of the 
penicillins and 
cephalosporins
TEM and SHV Enterobacteriaceae 
(K. pneumoniae,  
E. coli, E. cloacae)
A 2be Extended 
spectrum-β- 
lactam drugs, 
monobactam
Hydrolysis 
of extended 
spectrum-β- 
lactam drugs
TEM, SHV and 
CTX-M
Enterobacteriaceae 
(K. pneumoniae,  
E. coli, E. cloacae)
A 2br Penicillins Resistant 
to β-lactam 
inhibitor
TEM and SHV Enterobacteriaceae 
(K. pneumoniae,  
E. coli, E. cloacae)
A 2c Carbenicillin Hydrolysis of 
carbenicillin
CARB Enterobacteriaceae 
(K. pneumoniae,  
E. coli, E. cloacae)
A 2ce Carbenicillin 
and Cefepime
Hydrolysis of 
carbenicillin and 
cefepime
RTG
B (B1) 3a Carbapenems Carbapenems but 
not aztreonam
IMP, VIM and 
NDM
Enterobacteriaceae 
(K. pneumoniae, 
E. coli), non-
fermenters  
(P. aeruginosa,  
A. baumannii)
B (B2) 3b Carbapenems Prefer to 
hydrolyze 
carbapenems
CphA and Sfh
C 1 Cephalosporins More 
hydrolyze the 
cephalosporins
AmpC,
C 1e Cephalosporins Highly 
hydrolyzed the 
ceftazidime
GC1, CMY-37
D 2d Oxacillin Hydrolysis of 
oxacillin
OXA-1, 
OXA-10
A. baumannii
D 2de Extended 
spectrum-β- 
lactam drugs
Hydrolysis 
of extended 
spectrum-β- 
lactam drugs
OXA-11, 
OXA-50
A. baumannii
D 2df Carbapenems Hydrolysis of 
oxacillin and 
carbapenems
OXA-23 and 
OXA-48
A. baumannii
Table 1. 
Classification of the β-lactamases.
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K. pneumoniae. The most common genes of AmpC families that have been 
reported in K. pneumoniae are DHA, FOX, CMY and MOX types in different 
parts of the world. Although they are plasmid mediated however, first case 
of chromosomal mediated AmpC blaCMY-2 containing K. pneumoniae was 
reported in 2009. AmpC producing K. pneumoniae along with porin loss and 
increase efflux pump display increase resistance against β-lactam drugs which 
can lead to the carbapenem resistance in future [37].
4.4.4 Class A carbapenemases producing K. pneumoniae
Since the sporadic spread of ESBL producing K. pneumoniae in different 
regions, carbapenems which is considering last resort to treat infections caused 
by such pathogens have widely used. The extensive usage of carbapenems have 
led the emergence of plasmid mediated carbapenemase genes such as IMP, VIM, 
KPC and NDM. Carbapenemases are the potent enzymes that hydrolyzed the 
carbapenem drugs and left no treatment option available [32]. There are vari-
ous chromosomal mediated (SME, SFC and NMC-A) and plasmid mediated 
carbapenemases (KPC, GES, IMI) have been identified. It has determined that a 
carbapenemase has variants extending from KPC-1 to KPC-33 till now [28]. KPC 
gene is mainly located on different types of transmissible plasmids such as IncF, 
IncX, IncA/C, IncR and IncI2 which lead to the horizontal transfer of antimicro-
bial resistomes. These plasmids also acquired resistant genes of other antibiotics 
such as aminoglycosides, tetracycline and quinolones. Most of the KPC genes are 
associated with Tn4401 transposons which jumped from one plasmid to other 
[38]. the endemic of KPC producing K. pneumoniae identified in different parts of 
the world including USA, UK, Japan, China, Greece, India, Spain, Germany and 
Italy. Moreover, out breaks of the KPC also documented in different countries like 
USA, France (travelling history from the endemic area), Spain, Netherlands, UK, 
Finland and Sweden [39].
4.4.5 Class B carbapenemase producing K. pneumoniae
Class B are the MBLs that require Zn+ as a cofactor for their activity. There 
are many types of MBLs have been identified such as IMP, VIM, and NDM in 
Enterobacteriaceae. These enzymes cause resistance to various antibiotics includ-
ing carbapenems and left no treatment option [40]. NDM is one the potent 
enzyme of MBL that newly emerged in clinically isolates of K. pneumoniae and 
E. coli from a Swedish patient who had been hospitalised in New Delhi, India in 
2008. NDM producing bacteria displayed resistance not only against β-lactam 
drugs but also to other 14 classes of antibiotics. NDM producing bacteria 
notable K. pneumoniae and E. coli are major cause of morbidity and mortality 
in developing countries. Qamar et al. reported 4/9 children died due to NDM 
producing bacteria [12]. Similarly, another study from Karachi, Pakistan also 
documented 57% mortality in neonates due to NDM producing bacteria mainly 
K. pneumoniae [13]. Up till now there are 19 (NDM-1 to NDM-19) variants 
have been identified in different parts of the world [41]. Among these NDM-1, 
NDM-5 and NDM-7 are most prevalent variants with a hyper variable region. 
NDM are mainly plasmid mediated as compared to chromosome and located 
on different size and number of plasmids such as IncF, IncX, IncA/C. NDM 
producing K. pneumoniae are belong to various sequence types such as ST11, 
ST147, ST258, ST340, ST15 and ST16. More than 50% of the NDM producing 
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K. pneumoniae have been identified from ST11 and ST147. NDM genes are 
mainly associated with ISAba125 transposons in Enterobacteriaceae family 
which hypothesised originated from the Tn125 of A. baumannii [42]. Since the 
discovery of the NDM in Asia it is widely spread in different parts of the world 
including USA, UK, Middle East, Europe, Africa and Australia. Main reservoir 
for NDM are the Asian countries like India, Pakistan and China and the Balkan 
States [39].
4.4.6 Class D carbapenemases producing K. pneumoniae
These carbapenemase enzymes swiftly hydrolyzed the isoxazolylpenicillins 
drugs such as oxacillin, cloxacillins and dicloxacillin than benzylpenicillin. 
There are more than 574 variants have been identified around the globe but 
few of them have the carbapenemase activity. Therefore, class D are reclassi-
fied in to 12 main groups; Oxacillinase (OXA)-23, OXA-24, OXA-48, OXA-51, 
OXA-58, OXA-143, OXA134, OXA-211, OXA-213, OXA-214, OXA-229, OXA-235 
[43]. Among these most potent variants is OXA-48 which was firstly identified 
in K. pneumoniae in Turkey in 2003. Later, this gene spread in different parts 
of the world such as Libya, Egypt, India, Spain Switzerland, France, Germany, 
Argentine, Israel, Saudi Arabia, Japan. The highest percentage of OXA-48 has 
been reported in France, Spain and Saudi Arabia (78%) followed by 88% in 
Lebanon and 56% in Pennsylvania [39]. Co-existence of OXA-48 like K. pneu-
moniae has been reported from different countries like Switzerland (OXA-48/
NDM-1), Turkey (OXA-48/NDM-1) and India (OXA-181/VIM-5). OX-48 like 
genes are mainly present on transferable and conjugative group of plasmids 
(IncL/M and IncL) [39, 44].
5. Tacking of antibiotic resistance
AMR is becoming a menace to global health. According to United Nation 
(UN), in 2050, if we do not tackle the AMR now, more than 10 million people 
will die each year and the global income cost would be $100 trillion. So, in 2050, 
one person will die after every 3 seconds [7]. Firstly, it is need of the hour to give 
a public awareness through paper and electronic media to stop the irrational use 
of antibiotics. Secondly, people should improve their hygiene practices which 
will reduce the 60% antibiotics burden to reduce the diarrhoea. Thirdly, more 
than 70% world’s antibiotics are being utilised in agriculture and live stocks, 
so overuse of antibiotics must be avoided in these settings. Fourthly, Global 
surveillance of AMR should be conducted and maintained throughout the world. 
Fifthly, there are many countries which do not have the rapid and effective 
diagnostics facilities of microbiology which allow the physician to prescribe the 
broad-spectrum empirical therapy. Sixthly, there is an urgent need to develop an 
alternative method to treat the AMR such as vaccines, phage therapy, probiotics, 
antibodies and lysins. Seventhly, there are shortages of microbiologists, infec-
tious diseases specialists, infections control specialists, vegetarians, pharmacists 
and epidemiologists. Eighthly, A global funding must be required to support 
and encourage the less commercially attractive. Ninthly, the world gives better 
incentive to pharmaceutical companies to develop new and existing antibiotics. 
Finally, world leading organisations such as WHO, G20, UN must work together 
with coordination.
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